Sports
IND Application for a Phase III Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of
By: prnewswire_apac
- Oct 17 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS
Share this page
Guest Posts by Easy Branches
